815 / 1631
• Combined modality therapy has been the standard of care
for most patients with localized diffuse large B-cell
lymphoma (DLBCL), particularly those with limited stage
low risk disease or bulky sites.
|
|
815 / 1631
• Combined modality therapy has been the standard of care
for most patients with localized diffuse large B-cell
lymphoma (DLBCL), particularly those with limited stage
low risk disease or bulky sites.